TP53I11 (tumor protein p53 inducible protein 11) functions as a tumor suppressor that negatively regulates cell proliferation and metastasis through multiple mechanisms. The protein suppresses epithelial-mesenchymal transition (EMT) and cancer cell migration by reducing HIF1α expression levels under hypoxic conditions 1. TP53I11 enhances extracellular matrix-independent cell death (anoikis resistance) by modulating the balance between AKT and AMPK signaling pathways, functioning as a metabolic mediator that adapts cells to different cellular contexts 2. The protein plays a crucial role in endoplasmic reticulum calcium homeostasis, where it increases ER Ca2+ levels and inhibits cancer cell proliferation 3. TP53I11 is frequently downregulated in various cancers through microRNA-mediated mechanisms, including targeting by miR-645 in non-small cell lung cancer 4 and miR-1234 in gastric cancer 5. Hyperbaric oxygen therapy upregulates TP53I11 expression as part of its anti-glioblastoma effects, promoting apoptosis 6. Clinical significance is evidenced by improved overall survival rates in patients with low TP53I11 expression in ocular melanoma 7, though this paradoxical finding may reflect context-dependent functions. The gene represents a potential therapeutic target for cancer intervention through ER calcium modulation strategies.